Meeting
2011 ASCO Annual Meeting
Randomized phase II study of R-CHOP plus enzastaurin versus R-CHOP in the first-line treatment of patients with intermediate- and high-risk diffuse large B-cell lymphoma (DLBCL): Preliminary analysis.
Authors
J. D. Hainsworth
Sarah Cannon Research Institute, Nashville, TN
J. D. Hainsworth , E. Arrowsmith , M. McCleod , L. Fayad , O. Hamid , L. Davis , B. K. Lin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Lymphoma
Clinical Trial Registration Number
NCT00451178
Citation
J Clin Oncol 29: 2011 (suppl; abstr 8016)
Abstract #
8016
Poster Bd #
2
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high/high-intermediate risk diffuse large B-cell lymphoma.
First Author: N. M. Reddy
Poster
2023 ASCO Annual Meeting
Phase II trial of split-dose R-CHOP for older patients with diffuse large B-cell lymphoma (DLBCL).
First Author: Nirav Niranjan Shah
Poster
2023 ASCO Annual Meeting
Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL.
First Author: Carrie Ho
Poster
2022 ASCO Annual Meeting
First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) + R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): Phase 1/2 data update.
First Author: Lorenzo Falchi